Neurology
-
Randomized Controlled Trial
Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. ⋯ This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.
-
Randomized Controlled Trial
Repetitive TMS does not improve cognition in patients with TBI: A randomized double-blind trial.
To determine whether high-frequency repetitive transcranial magnetic stimulation (rTMS) improves cognition in patients with severe traumatic brain injury. ⋯ This study provides Class II evidence that for individuals with chronic DAI, high-frequency rTMS over the left DLPFC does not significantly improve cognition.
-
Randomized Controlled Trial
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment. ⋯ This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.
-
Randomized Controlled Trial Multicenter Study
Framing advance care planning in Parkinson disease: Patient and care partner perspectives.
Advance care planning (ACP) is a core quality measure in caring for individuals with Parkinson disease (PD) and there are no best practice standards for how to incorporate ACP into PD care. This study describes patient and care partner perspectives on ACP to inform a patient- and care partner-centered framework for clinical care. ⋯ ACP in PD may be influenced by patient and care partner perceptions and misperceptions, symptoms of PD (e.g., apathy, cognitive dysfunction, disease severity), and models of clinical care. Optimal engagement of patients with PD and care partners in ACP should proactively address misperceptions of ACP and utilize clinic teams and workflow routines to incorporate ACP into regular care.
-
Randomized Controlled Trial
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
To determine the effect of erenumab, a human anti-calcitonin gene-related peptide receptor monoclonal antibody, in patients with chronic migraine and medication overuse. ⋯ This study provides Class II evidence that erenumab reduces monthly migraine days at 3 months in patients with chronic migraine and medication overuse.